However, the paucity of established preclinical models able to faithfully recapitulate the genetic landscape, tumor microenvironment, and growth patterns of IDH-mutated LGGs has made it extremely challenging for the investigation of the role of IDH mutations in glioma development and progression, and, consequently, of the therapeutic efficacy of IDH inhibitors. This evidence concerns the gene IDH2 and neoplasm.